Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VRNA
stocks logo

VRNA

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
11 Analyst Rating
up Image0
Wall Street analysts forecast VRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRNA is 118.00 USD with a low forecast of 90.00 USD and a high forecast of 170.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 104.900
sliders
Low
90.00
Averages
118.00
High
170.00
up Image0
Current: 104.900
sliders
Low
90.00
Averages
118.00
High
170.00
H.C. Wainwright
Raghuram Selvaraju
Buy
to
Neutral
downgrade
$90 -> $107
2025-07-14
New
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$90 -> $107
2025-07-14
New
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright analyst Raghuram Selvaraju downgraded Verona Pharma to Neutral from Buy with a price target of $107, up from $90, after Merck said it will acquire Verona for $107 per American depository share. The firm does not expect any competitors to attempt to outbid Merck.
Roth Capital
Boobalan Pachaiyappan
Buy -> Neutral
downgrade
$116 -> $107
2025-07-10
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$116 -> $107
2025-07-10
downgrade
Buy -> Neutral
Reason
Roth Capital analyst Boobalan Pachaiyappan downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of $107, down from $116, following Merck's (MRK) $10B proposal to acquire all Verona for $107 per share or $10B.
Wolfe Research
Outperform -> Peer Perform
downgrade
2025-07-10
Reason
Wolfe Research
Price Target
2025-07-10
downgrade
Outperform -> Peer Perform
Reason
Wolfe Research downgraded Verona Pharma (VRNA) to Peer Perform from Outperform without a price target after Merck (MRK) announced it will acquire Verona for $10B or $107 per share.
Truist
Buy
to
Hold
downgrade
$100 -> $107
2025-07-10
Reason
Truist
Price Target
$100 -> $107
2025-07-10
downgrade
Buy
to
Hold
Reason
Truist downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from $100, following Merck's (MRK) $10B proposal to acquire all Verona for $107 per share or $10B. Verona's Ohtu makes sense as the "anchor" drug to help grow Merck's existing footprint in respiratory franchise and be competitive against dupi, IL33s and more, the analyst tells investors in a research note.
Piper Sandler
Overweight -> Neutral
downgrade
$160 -> $107
2025-07-10
Reason
Piper Sandler
Price Target
$160 -> $107
2025-07-10
downgrade
Overweight -> Neutral
Reason
Piper Sandler downgraded Verona Pharma (VRNA) to Neutral from Overweight with a price target of $107, down from $160, after Merck (MRK) announced it will acquire Verona for $10B or $107 per share.
Jefferies
Jefferies
Buy
to
Hold
downgrade
$140 -> $107
2025-07-09
Reason
Jefferies
Jefferies
Price Target
$140 -> $107
2025-07-09
downgrade
Buy
to
Hold
Reason
Jefferies downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, down from $140, after the company entered into an agreement under which Merck (MRK) will acquire it for $107 per American depository share, or $10B. Jefferies sees no regulatory risks for the deal.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Verona Pharma PLC (VRNA.O) is 93.56, compared to its 5-year average forward P/E of -68.40. For a more detailed relative valuation and DCF analysis to assess Verona Pharma PLC 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-68.40
Current PE
93.56
Overvalued PE
243.11
Undervalued PE
-379.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-11.25
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
23.41
Undervalued EV/EBITDA
-45.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
76.78
Current PS
18.37
Overvalued PS
218.51
Undervalued PS
-64.96

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

VRNA News & Events

Events Timeline

(ET)
2025-07-09
09:00:15
Video: Verona Pharma jumps after agreeing to be acquired by Merck for $10B
select
link
2025-07-09
06:33:02
Merck to acquire Verona Pharma for $107.00 per ADS
select
2025-07-09
06:02:33
Merck in talks to buy Verona Pharma for $10B, FT reports
select
link
Sign Up For More Events
Sign Up For More Events

News

Preview
7.0
07-14Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRNA, KLG, MRGM, SONN on Behalf of Shareholders

  • Investigation of Companies: Halper Sadeh LLC is investigating Verona Pharma, WK Kellogg Co, Monogram Technologies Inc., and Sonnet BioTherapeutics, Inc. for potential violations of federal securities laws related to their recent sales and mergers.

  • Legal Rights for Shareholders: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options regarding these transactions, with no upfront legal fees required.

Preview
4.0
07-14Benzinga
This Procter & Gamble Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

  • Analyst Downgrades: Several Wall Street analysts downgraded their ratings on major companies, including Best Buy, Henry Schein, and Procter & Gamble, with lowered price targets reflecting a more cautious outlook.

  • Stock Performance: Despite the downgrades, some companies like Verona Pharma saw an increase in their price target, while Vestis Corporation's rating was downgraded but its price target was raised slightly.

Preview
7.0
07-14PRnewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRNA, KLG, VBTX on Behalf of Shareholders

  • Investigation of Companies: Halper Sadeh LLC is investigating Verona Pharma, WK Kellogg Co, and Veritex Holdings for potential violations of federal securities laws and breaches of fiduciary duties related to their recent sales.

  • Legal Support for Shareholders: The firm offers free consultations to shareholders regarding their legal rights and options, aiming to seek increased compensation or additional disclosures on behalf of investors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Verona Pharma PLC (VRNA) stock price today?

The current price of VRNA is 104.9 USD — it has increased 0.11 % in the last trading day.

arrow icon

What is Verona Pharma PLC (VRNA)'s business?

Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

arrow icon

What is the price predicton of VRNA Stock?

Wall Street analysts forecast VRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRNA is 118.00 USD with a low forecast of 90.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Verona Pharma PLC (VRNA)'s revenue for the last quarter?

Verona Pharma PLC revenue for the last quarter amounts to 60.57M USD, decreased % YoY.

arrow icon

What is Verona Pharma PLC (VRNA)'s earnings per share (EPS) for the last quarter?

Verona Pharma PLC. EPS for the last quarter amounts to -0.02 USD, decreased -33.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Verona Pharma PLC (VRNA)'s fundamentals?

The market is revising Upward the revenue expectations for Verona Pharma plc (VRNA) for FY2025, with the revenue forecasts being adjusted by 27.58% over the past three months. During the same period, the stock price has changed by 74.63%.
arrow icon

How many employees does Verona Pharma PLC (VRNA). have?

Verona Pharma PLC (VRNA) has 209 emplpoyees as of July 19 2025.

arrow icon

What is Verona Pharma PLC (VRNA) market cap?

Today VRNA has the market capitalization of 8.93B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free